1. Home
  2. LUV vs BIIB Comparison

LUV vs BIIB Comparison

Compare LUV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Airlines Company

LUV

Southwest Airlines Company

HOLD

Current Price

$38.74

Market Cap

21.3B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.32

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUV
BIIB
Founded
1967
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3B
27.1B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
LUV
BIIB
Price
$38.74
$183.32
Analyst Decision
Hold
Buy
Analyst Count
19
27
Target Price
$45.39
$194.72
AVG Volume (30 Days)
9.3M
827.4K
Earning Date
04-27-2026
01-01-0001
Dividend Yield
1.86%
N/A
EPS Growth
3.95
N/A
EPS
0.79
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$14.29
N/A
Revenue Next Year
$5.08
N/A
P/E Ratio
$48.87
$21.03
Revenue Growth
N/A
2.22
52 Week Low
$23.82
$110.04
52 Week High
$55.11
$202.41

Technical Indicators

Market Signals
Indicator
LUV
BIIB
Relative Strength Index (RSI) 28.87 46.95
Support Level $30.45 $181.24
Resistance Level $44.28 $186.17
Average True Range (ATR) 2.04 5.30
MACD -1.35 -1.14
Stochastic Oscillator 4.61 16.93

Price Performance

Historical Comparison
LUV
BIIB

About LUV Southwest Airlines Company

Southwest Airlines is the largest domestic air carrier in the United States by passengers boarded. Southwest operates nearly 800 aircraft in an all-Boeing 737 fleet. Despite offering some longer routes and a few perks for business travelers, the airline predominantly specializes in short-haul, leisure flights operated in a single, open-seating cabin configuration in a point-to-point network. In early 2026, Southwest will modify its cabins to offer some rows with extra legroom and will update its ticketing process and merchandising to offer assigned seats and more fare categories, including a basic economy class that will more directly compete with other airlines' offerings and appear for the first time in travel aggregators' search results.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: